How To Listen
Barbora de Courten, PhD
Professor Barbora de Courten, MD PhD FRACP MPH is a Professor at Monash University, Australia. She is a National Heart Foundation Future Leader Fellow and a specialist physician with a PhD in epidemiology, extensive training in clinical trials (NIH) and a Master of Public Health (Monash University). She has expertise across the translational research continuum from epidemiology, human mechanistic studies to clinical trials and public health interventions through to practice.
She is passionate about research into holistic approaches to prevention and treatment of chronic diseases by promoting health through safe, low-cost and easily scalable interventions with the potential to have an immediate public health impact to prevent and treat chronic diseases. She believes this will impact not only health of individuals but also be beneficial to our society and environment we live in.
Her vision is to establish new strategies for prevention and management of chronic diseases, specifically obesity, diabetes and cardiovascular disease. Her goal is that her research findings will ultimately translate into treatment guidelines, reduced diabetes and cardiovascular morbidity and mortality and reduced healthcare costs.
In This Episode We Discuss
- Mechanisms by which certain behaviours (inactivity, poor diet, smoking, etc.) increase chronic disease risk: inflammation, oxidative stress and advanced glycation (AGE formation).
- What is carnosine?
- How might carnosine supplementation reduce risk?
- Dosage and timing used in trials to date
- Prof. de Courten’s trial showing improvements in insulin sensitivity and an oral glucose tolerance test
- As beta-alanine works by increasing muscle carnosine concentration, could it be useful for the health?
Links & Resources
- de Courten et al., 2015 – Muscle Carnosine Is Associated with Cardiometabolic Risk Factors in Humans
- de Courten et al., 2016 – Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial
- Baye et al., 2016 – Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease
- Derave et al., 2019 – An update on carnosine and anserine research